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Intravenous immunoglobulin (IVIg) is the gold-standard for maintenance treatment of multifocal
motor neuropathy (MMN). This phase III, randomised, double-blind, multi-centre, active-control,
crossover study, aimed to evaluate the non-inferiority of IqYmune® relative to Kiovig®, primarily
based on efficacy criteria. Twenty-two adult MMN patients, treated with any brand of IVIg
(except Kiovig® or IqYmune®) at a stable maintenance dose within the range of 1 to 2 g/kg
every 4 to 8 weeks, were randomised to receive either Kiovig® followed by IqYmune®, or
IqYmune® followed by Kiovig®. Each product was administered for 24 weeks. The primary end-
point was the difference between IqYmune® and Kiovig® in mean assessments of modified
Medical Research Council (MMRC) 10 sum score (strength of 5 upper-limb and 5 lower-limb
muscle groups, on both sides, giving a score from 0 to 100) during the evaluation period (non-
inferiority margin of Δ = 2). A linear mixed model analysis demonstrated the non-inferiority of
IqYmune® relative to Kiovig®, independently of the covariates (value at baseline, treatment
period, and treatment sequence). The estimated “IqYmune® − Kiovig®” difference was −0.01,
with a 95% confidence interval (CI) −0.51 to 0.48. The number of adverse reactions (ARs) and
the percentage of patients affected were similar for the two products: 39 ARs in 10 patients
with IqYmune® vs 32 ARs in 11 patients with Kiovig®. No thromboembolic events nor haemoly-
sis nor renal impairment were observed. In this first clinical trial comparing two IVIg brands for
maintenance treatment of MMN, efficacy and tolerability of both brands were similar.
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1 | INTRODUCTION
Intravenous immunoglobulin (IVIg) is the gold-standard first-line treat-
ment for multifocal motor neuropathy (MMN), recommended by both
European Federation of Neurological Societies/Peripheral Nerve Soci-
ety (EFNS/PNS) for MMN management,1 and European Federation of
Neurological Societies (EFNS) Guidelines for the use of IVIg to treat
neurological diseases.2 Randomised controlled trials have shown that
IVIg improves muscle strength and reduces disability in MMN.3 Pro-
longed remission has been observed after IVIg therapy,4 but only in
rare cases. In most cases, repeated courses of IVIg treatment are
required to maintain the beneficial effects.
Several brands of IVIg have received approval for use for MMN in
individual European countries but only one brand (Kiovig® Baxter) has
received approval by the European Medicines Agency (in 2011) and
the US Food and Drug Administration (in 2012).
IqYmune® is a highly purified 10% liquid preparation of normal human
immunoglobulin for intravenous administration that has been shown to
be effective and well-tolerated in patients with primary immunodefi-
ciency.5 It has been approved since 2015 in Europe, as a replacement
therapy for primary immunodeficiency syndrome and for various types of
hypogammaglobulinemia, and for immunomodulation in primary immune
thrombocytopenia, Guillain-Barré syndrome, and Kawasaki disease.
The immunomodulatory properties of IqYmune® made it worth
investigating its value as a maintenance treatment for MMN. This study
comparing IqYmune® with an active control was approved at a scientific
advice meeting with the European Medicines Agency in January 2012.
This study aimed to determine whether IqYmune® is non-inferior
to Kiovig®, primarily based on efficacy criteria. Investigation of the
safety of IqYmune® was a secondary objective.
2 | PATIENTS AND METHODS
2.1 | Study design and treatment
This phase III randomised, double-blind, active-control, crossover non-
inferiority trial was conducted at 14 sites in four countries (France,
United Kingdom, Italy, and Spain). The study protocol and its amend-
ments were approved by the Ethics Committees of all centres and
were authorised by the European Medicines Agency. The study was
conducted in accordance with the Declaration of Helsinki as amended
in 2013 and good clinical practice. All participants provided written
informed consent. The study is registered at ClinicalTrials.gov
(NCT01951924) and EudraCT (2012-001995-12).
Participants were randomised 1:1 to two sequence groups, via a
centralised interactive web response system. There was no predefined
randomisation list. Instead, assignment was done dynamically using
the minimisation method of Pocock and Simon6 to reduce the risk of
imbalanced treatment sequence assignment in sites and study. In case
of a treatment sequence imbalance within the site (or globally if bal-
ance was achieved within the site) a new subject was randomised with
a probability of 85% to the underrepresented sequence. If sequences
were balanced both within the site and globally, a new subject was
randomised between sequences using a probability of 50%.
The participants allocated to sequence A initially received Kiovig®
for 21 to 25 weeks (period 1) and were then treated with IqYmune®
for 21 to 25 weeks (period 2). The participants in sequence B received
IqYmune® during period 1, followed by Kiovig® in period 2. The evalu-
ation period ran from 13 weeks after the initiation of either IqYmune®
or Kiovig® until the end of the corresponding period.
Before shipment to investigational sites, each vial of product was
covered by a masking system and was packaged in an individual box.
Each vial and box was labelled with a unique identification number
and all other useful information for the study except information
enabling the identification of the product. Before each course, the
hospital pharmacist logged in the interactive web response system
and obtained the vial identification numbers for vials to be adminis-
tered to the subject. The hospital pharmacist finalised the blind aspect
of the vial by masking the vials' caps. The products were provided to
the investigator with a masking system and infusion lines, ready for
intravenous administration with a B-Braun infusion pump (Infusomat
Space). The dose and frequency of treatment were maintained at pre-
randomisation levels. The allowed range was between 1 g/kg over
1 to 3 days and 2 g/kg over 2 to 5 days every 4 to 8 weeks (7 days).
The maximum dose and frequency was 2 g/kg every 4 weeks.
After the initiation of the trial, two major modifications were made
to the exclusion criteria. Participants who had previously been treated
with Kiovig® could be enrolled, if they had not received Kiovig® during
the last 6 months. Given the half-life of Kiovig® in adults, this period
was considered sufficiently long to limit any potential carryover effect.
The potential risk of acute renal failure and renal monitoring in subjects
at risk were addressed by adding a urine protein reagent strip test
before the initiation of product administration and at all follow-up visits
for subjects with abnormal results for this test at screening or with a glo-
merular filtration rate (GFR) in the 60 to 80 mL/min/1.73 m2 range. The
exclusion limit for GFR was decreased from 80 to 60 mL/min/1.73m2.
An albumin-to-creatinine ratio >30 mg/mmol and a protein-to-
creatinine ratio >50 mg/mmol were added as exclusion criteria.
2.2 | Participant selection
Adult men and women (≥18 years old) were eligible for inclusion if they
had been diagnosed with probable or definite MMN according to the
European Federation of Neurological Societies/Peripheral Nerve Soci-
ety (EFNS/PNS) 2010 guidelines,1 and were being treated with a stable
maintenance dose, within a 15% range, of any brand of IVIg (Kiovig®
excluded during the last 6 months before enrolment) at a dose between
1 g/kg over 1 to 3 days and 2 g/kg over 2 to 5 days every 4 to 8 weeks
(7 days) for at least 3 months before enrolment. The main exclusion
criteria were known hypersensitivity to Ig therapy, anti-IgA antibodies,
GFR <60 mL/min/1.73 m2 estimated by the Modification of Diet in
Renal Disease equation in adults, serum levels of alanine aminotransfer-
ase or aspartate aminotransferase >2 times the upper limit of the nor-
mal range, protein-losing enteropathy or nephrotic syndrome,
pregnancy, breastfeeding, or a history of thrombosis.
2.3 | Outcome measures
The primary efficacy outcome was the Modified Medical Research
Council (MMRC) sum score of 10 predetermined muscle groups, as
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described by Cats et al,7 during the evaluation period. Five muscle
groups from the arm and five from the leg were tested (Table 1). Each
muscle group was scored from 0 (paralysis) to 5 (normal strength) and
10 movements were assessed on both sides, resulting in a total score
between 0 (complete paralysis) and 100 (full strength).
Secondary efficacy outcomes included the MMRC new 10-sum
score developed specifically for this study, the Rasch-built MMRC
10-sum score,7 the MMRC 14-sum score (Table 1), grip strength mea-
sured with a dynamometer for the most affected hand and disability
in daily activities, as assessed with the inflammatory neuropathy
course and treatment (INCAT) disability score8 as used in MMN by
Stangel et al.9 Total score on this scale ranges from 0 (no signs of dis-
ability) to 10 (most severe disability score) and the upper-limb sub-
score ranges from 0 to 5.
Throughout the study, safety was evaluated by assessing the
occurrence of adverse events (AEs) and their relationship to the prod-
uct. A physical examination was performed and vital signs, biochemi-
cal, and haematological parameters were also monitored.
2.4 | Statistics
Sample size for the non-inferiority test comparing IqYmune® and
Kiovig® was calculated based on the primary criterion of MMRC
10-sum score, assuming no difference between treatments. A differ-
ence ≤2 points in MMRC 10-sum score between the two products
was considered not to be clinically meaningful. With a non-inferiority
margin of 2, a within-participant error variance of 2.5, a one-tailed α
risk of 2.5% and 90% power, 16 evaluable participants were required
to achieve a lower confidence interval (CI) boundary ≥−2 for the
IqYmune®-Kiovig® difference, assuming a true difference of 0.
The analysis of efficacy endpoints was based on a linear mixed
model, to obtain a 95% CI for the difference between IqYmune® and
Kiovig®. The model included subject as a random effect, and product
(IqYmune®/Kiovig®), period (1/2) and sequence (A/B) as fixed effects,
with baseline value (ie, before the start of the first period) as a contin-
uous fixed-effect covariate.
The non-inferiority of IqYmune® relative to Kiovig® was assessed
in one-tailed tests with a nominal α risk of 2.5%. Non-inferiority was
considered to be demonstrated if the lower limit of the 95% CI of the
difference (IqYmune® − Kiovig®) was greater than −2.
The total treated set (TTS) was defined as all subjects receiving at
least one dose of product. The modified intent-to-treat (mITT) popula-
tion was defined as all randomised subjects receiving at least one
administration of product, for whom a baseline level and at least one
post-treatment MMRC efficacy assessment were available. The per
protocol set (PPS) was defined as all subjects from the mITT popula-
tion completing the protocol without deviation (as assessed during
the protocol deviation review meeting before unblinding) likely to
affect the statistical analysis.
For efficacy evaluations, the mITT population was used for the
primary analysis and the per-protocol set was used for the secondary
analysis. Sensitivity analyses were also performed on these populations.
The TTS was defined as all subjects who received at least one dose of
investigated medicinal product. The TTS was used for all safety analyses.
3 | RESULTS
3.1 | Participant characteristics and treatment
Between October 2013 and July 2015, 30 participants were screened,
and 23 participants were randomised to sequence A (Kiovig® then
TABLE 1 Muscle groups tested for each MMRC sum score
Muscle groups tested on both sides
MMRC 10-sum
score
MMRC new 10-
sum score
MMRC 14-
sum score
Rasch-built MMRC
10-sum score
Upper limbs
Shoulder abductors + + + +
Elbow flexors + + + +
Elbow extensors + + + +
Wrist extensors + + + +
Wrist flexors + + +
Finger flexors + +
Finger extensors at metacarpophalangeal joints + +
Thumb abductor + +
Index finger abductor + +
Lower limbs
Hip flexors + + +
Knee flexors + + +
Knee extensors + + +
Foot dorsal flexors + + + +
Foot plantar flexors + + + +
Total scorea 0-100 0-100 0-140 0-60
Abbreviations: +, muscle groups tested; MMRC, Modified Medical Research Council.
a MMRC 10-sum score and MMRC new 10-sum score, MMRC 14-sum score: each muscle group is scored from 0 (paralysis) to 5 (normal strength),
Rasch-built MMRC 10-sum score: each muscle group is scored from 0 (paralysis) to 3 (normal strength)—a higher value indicates better muscle strength.
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IqYmune®; N = 12) or B (IqYmune® then Kiovig®; N = 11). One partici-
pant randomised to sequence B was excluded before the first dose
administration because the previous IVIg dose was not stable. Twenty-
two participants received at least one course of product. One partici-
pant in sequence B withdrew his consent 4 months after treatment ini-
tiation, due to dissatisfaction with study treatment. This participant was
not excluded from any of the populations for analysis. A flow chart
summarising the distribution of the participants is provided in Figure 1.
The baseline characteristics of the patients were similar in the two
groups (Table 2). Most of the participants were men. Median age was
48.0 years, and there was one patient over the age of 75 years. Sixteen
of the 22 participants (72.7%) had at least one relevant concomitant
disease in their medical or surgical history. Vascular disorders were the
most frequent and were found in seven (31.8%) participants. All partici-
pants had already been on a stable dose of IVIg therapy for MMN for
at least 3 months before inclusion in the study. The median time from
initial diagnosis to entry into this study was 4.3 years.
3.2 | Efficacy
Sensitivity analysis and analysis of efficacy endpoints were performed
on the mITT and PPS populations (Figure 1).
3.2.1 | Primary efficacy criterion: Mean MMRC sum score
during the evaluation period
The comparison test was based on a linear-mixed model estimating
the effect of product, period, and sequence. The estimates of the
effects of each of these three factors were adjusted for the other two
factors and for baseline MMRC 10-sum score.
No sequence or period effect was detected. The non-inferiority
of IqYmune® relative to Kiovig® was demonstrated: the estimated dif-
ference between IqYmune® and Kiovig® was −0.01, with a 95% CI of
[−0.51, 0.48] for the mITT population (Figure 2) and −0.14 [−0.60,
0.31] for the PPS (Table 3). The associated P-values for non-inferiority
were <0.0001.
N = 23
Randomized Set
Patients who signed an 
informed consent form
N = 30
Sequence A
Period 1: Kiovig® -Period 2: IqYmune®
N = 12 N = 10
Sequence B
Period 1: IqYmune® -Period 2: Kiovig®
N = 12
Total Treated Set N=22
N = 10mITT N=22
N = 12
Completed study
N = 9
Completed study
N =1 
Early withdrawal from the study 
during period 1 due to 
dissatisfaction with treatment
N =1 
Patient withdrawn post-
randomization and not treated
N = 11 N = 10PPS N=21
Excluded N=7
-GFR value out of range (N=3)
-Non stable IVIg*dose (N=3)
-Pancytopenia (N=1)
FIGURE 1 Participants disposition. GFR, glomerular filtration rate; IVIg, intravenous immunoglobulin; mITT, modified intent-to-treat; PPS, per
protocol set
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3.2.2 | Secondary efficacy criteria
Using the same linear-mixed model as for the primary endpoint, no sta-
tistically significant difference between IqYmune® and Kiovig® was
detected for the MMRC new 10-sum score, the Rasch-built MMRC
10-sum score, the MMRC 14-sum score, total INCAT disability score or
normalised grip strength measured during the evaluation period
(Table 4). The improvement in clinical global impression (CGI) measured
at the end of each period was also similar for the two products, with no
specific change observed in more than half of the participants (Table 5).
3.3 | Safety
The population used for the evaluation of safety consisted of the
22 participants who received at least one infusion of product. Partici-
pant exposure levels were similar for IqYmune® and Kiovig® (Table 6).
Both products were well-tolerated. There were no significant dif-
ferences between IqYmune® and Kiovig® in the number of commonly
reported AEs. None of the observed AEs was serious, and all resolved
without sequelae. Of the 161 AEs reported in 17 (77.3%) participants,
71 were considered related to the investigated medicinal product,
32 of these events occurring in 11 (52.4%) participants receiving
Kiovig® and 39 in 10 (45.5%) participants receiving IqYmune®
(Table 7). The most common AEs were headache and fatigue, for both
products (Table 7). One participant had a single episode of severe
headache attributed to IqYmune®; this episode lasted 2 days and
resolved with medication without sequelae.
Haematological and biochemical parameters before and after
each course revealed no signs of haemolysis or renal impairment with
either Kiovig® or IqYmune (data not shown). No thromboembolic
events occurred in any of the participants.
4 | DISCUSSION
This phase III randomised, comparative, active-control, double-blind
study with a crossover design demonstrated the non-inferiority both
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FIGURE 2 Geometric boxplots of modified Medical Research Council
(MMRC) 10-sum scores at baseline and 6 months after each
treatment sequence. Modified intent-to-treat, mITT population. The
lower limit of a box represents the first quartile, that is, 25% of data
lie below this value; the upper limit of the box represents the third
quartile, that is, 25% of the data lie above this value; the horizontal
line within the box indicates the median, that is, 50% of data lie above
this value. The diamond represents the mean value of the distribution,
and the dots outside the box represent outliers. This figure shows
that the medians after IqYmune® treatment and Kiovig® treatment
are similar to the baseline value and that the distributions are not
significantly different
TABLE 2 Baseline demographic and clinical characteristics of the
participants with MMN
Sequence Ad
N = 12
Sequence Bd
N = 10
Male: female ratio, n (%) 11 (91.7):1 (8.3) 8 (80.0):2 (20.0)
Age (y)
Median (min, max) 47.0 (32.0, 78.0) 49.0 (31.0, 64.0)
BMI (kg/m2)a
Median (min, max) 26.3 (18.1, 32.8) 24.7 (22.2, 35.1)
European Federation of Neurological Societies/Peripheral Nerve Society
diagnostic criteria, n (%)
Definite 11 (91.7) 8 (80.0)
Probable 1 (8.3) 2 (20.0)
Time since first symptoms (y)b
Median (min, max) 5.4 (1.0, 18.0) 8.3 (1.8, 20.5)
Time since diagnosis (y)b
Median (min, max) 3.4 (0.4, 9.8) 4.7 (1.2, 20.5)
Prior treatment of MMN other than IVIg since diagnosis, n (%)
Immunosuppressive 1 (8.3%) 3 (30.0%)
Otherc 1 (8.3%) 0
MMRC 10-sum score
Median (min, max) 97.5 (84.0, 100.0) 96.0 (60.0, 100.0)
MMRC new 10-sum score
Median (min, max) 93.0 (63.0, 97.0) 95.0 (45.0, 99.0)
Rasch-built MMRC 10-
sum score
Median (min, max) 58.0 (47.0, 60.0) 56.5 (34.0, 60.0)
MMRC 14-sum score
Median (min, max) 133.0 (98.0, 137.0) 135.0 (74.0, 139.0)
Total INCAT disability
score
Median (min, max) 2.0 (1.0, 6.0) 3.5 (0.0, 5.0)
Normalised grip
strength (%)
Median (min, max) 60.0 (0.0, 130.0) 72.0 (6.0, 115.0)
Abbreviations: BMI, body mass index; IVIg, intravenous immunoglobulin,
MMN, multifocal motor neuropathy.
Modified Medical Research Council (MMRC) 10-sum score and MMRC
new 10-sum score (range 0-100), MMRC 14-sum score (range 0-140),
Rasch-built MMRC 10-sum score (range 0-60), a higher value indicates
better muscle strength; Total INCAT disability score (range 0-10), a higher
value indicates maximal disability.
a BMI = weight (kg)/height (m)2.
b Time derived as: (screening date − event date)/365.25.
c Participant was treated with gabapentin, chloraminophene, cetirizine,
and prednisolone.
d In sequence A, participants were treated first with Kiovig® for 21 to
25 weeks (period 1) then with IqYmune® for 21 to 25 weeks (period 2).
In sequence B, participants were treated first with IqYmune® and then
with Kiovig®.
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in efficacy and safety of IqYmune® compared with Kiovig® for the
maintenance treatment of MMN.
The non-inferiority margin of two points for MMRC 10-sum score
mean between the two products was considered adequate. MMN is a
rare, slowly progressing disease. A crossover design was also consid-
ered appropriate for this study. One weakness of crossover trials is
the carryover effect across periods. The 12 weeks during which no
assessments were made at the start of each period were considered
to constitute an adequate wash-out phase to prevent carryover
effects from previous IVIg treatment.
The non-inferiority of IqYmune® treatment was established by
direct comparison with an active control of proven efficacy. The com-
parator, Kiovig® has been shown to be more effective than placebo
for the maintenance therapy of MMN7,10 and has had the European
Medicines Agency approval since 2011 and the Food and Drug
Administration approval since 2012. In the double-blind placebo-
controlled study performed by Hahn, the mean maximal grip strength
of the most affected hand of adults with MMN increased slightly on
Kiovig® treatment (3.75%) but deteriorated by 31.4% on placebo
(P = 0.005). Hahn et al, also reported that Guy's Neurological Disabil-
ity Scale11 scores worsened in 35.7% of participants during placebo
treatment, but not during Kiovig® treatment. Similarly, in the prospec-
tive open-label, non-controlled study performed by Cats et al, muscle
strength and disability scores remained stable in MMN patients during
Kiovig® treatment.7
The non-inferiority of IqYmune® treatment was demonstrated in
both the modified intention-to-treat and per protocol populations. The
PPS consisted of all participants completing the full course of assigned
treatment with no major protocol violations. The adult participants in
this study had all been diagnosed with MMN, on the basis of their
signs and symptoms, according to the EFNS/PNS 2010 guidelines.1
Muscle/grip strength and weakness were assessed with scales previ-
ously used in other trials in participants with immune neuropathies12
and MMN.7 The use of the MMRC 10-sum score for assessing muscle
strength in MMN was approved by the European Medicines Agency
TABLE 3 Primary efficacy outcome-estimated means of MMRC
10-sum score 13 to 26 weeks after the start of administration for
each product, linear mixed model—mITT and PPS
Population Covariate
Least square
means: estimate
[95% CI]
Differences:
estimate [95% CI] P value
mITT
N = 22
Product
IqYmune® 94.5 [93.5, 95.6] −0.01 [−0.51, 0.48] 0.96
Kiovig® 94.5 [93.6, 95.5]
Perioda
1 94.4 [93.4, 95.4] −0.24 [−0.73, 0.25] 0.32
2 94.7 [93.7, 95.6]
Sequencea
A 95.0 [93.9, 96.0] 0.90 [−0.85, 2.65] 0.30
B 94.1 [92.58,
95.61]
Non-inferiority IqYmune® vs Kiovig® <0.001
PPS
N = 21
Product
IqYmune® 94.4 [93.3, 95.6] −0.14 [−0.60, 0.31] 0.51
Kiovig® 94.6 [93.6, 95.5]
Perioda
1 94.3 [93.2, 95.5] −0.37 [−0.83, 0.08] 0.10
2 94.7 [93.7, 95.6]
Sequencea
A 94.9 [93.8, 96.0] 0.80 [−1.06, 2.67] 0.38
B 94.1 [92.5, 95.7]
Non-inferiority IqYmune® versus Kiovig® <0.001
Abbreviations: CI, confidence interval; MMRC, Modified Medical Research
Council.
Range of mean MMRC 10-sum score result: 0 (complete paralysis) to
100 (full strength). Modified-intent-to-treat (mITT), and per protocol set
(PPS) populations.
a In sequence A, participants were first treated with Kiovig® for
21-25 weeks (period 1) then with IqYmune® for 21-25 weeks (period 2).
In sequence B, participants were first treated with IqYmune® then with
Kiovig®.
TABLE 4 Secondary efficacy outcome assessments during the
13 weeks after the initiation of treatment with each product, linear
mixed model—mITT population
Covariate:
product
Least square means:
estimate [95% CI]
Differences: estimate
[95% CI] P value
MMRC new 10-sum score
IqYmune® 88.8 [87.2, 90.4] 0.15 [−0.56, 0.85] 0.67
Kiovig® 88.7 [87.3, 90.1]
Rasch-built MMRC 10-sum score
IqYmune® 55.9 [55.3, 56.4] 0.12 [−0.22, 0.46] 0.46
Kiovig® 55.7 [55.2, 56.3]
MMRC 14-sum score
IqYmune® 127.6 [125.6, 129.7] 0.10 [−0.65, 0.85] 0.79
Kiovig® 127.5 [125.8, 129.3]
Total INCAT disability score
IqYmune® 2.5 [2.21, 2.74] −0.03 [−0.29, 0.23] 0.7974
Kiovig® 2.5 [2.32, 2.71]
Normalised grip strength (%)
IqYmune® 52.3 [47.0, 57.7] −1.53 [−5.80, 2.73] 0.46
Kiovig® 53.9 [49.4, 58.3]
Abbreviations: CI, confidence interval
Modified Medical Research Council (MMRC) new 10-sum score (range
0-100), Rasch-built MMRC 10-sum score (range 0-60), MMRC 14-sum
score (range 0-140), a higher value indicates better muscle strength; Total
INCAT disability score (range 0-10), a higher value indicates maximal dis-
ability. Modified-intent-to-treat population (mITT, N = 22).
TABLE 5 Clinical global impression, by product, measured at the end
of each evaluation period
IqYmune®
N = 22
Kiovig®
N = 21
Rate of global improvement
1 = Very much improved 0 0
2 = Much improved 3 (13.6) 2 (9.5)
3 = Minimally improved 5 (22.7) 5 (23.8)
4 = No change 12 (54.5) 12 (57.1)
5 = Minimally worse 2 (9.1) 2 (9.5)
6 = Much worse 0 0
7 = Very much worse 0 0
Data are numbers (%) of participants.
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during the scientific advice meeting. The MMRC new 10-sum score
focuses more strongly on the upper limbs than the original MMRC
10-sum score. Based on the results obtained in Cats cross-sectional
study,13 this scale, developed by disease experts, includes clinically
relevant distal upper limbs muscle commonly affected in MMN and
excludes irrelevant lower limb muscles not usually affected in MMN.
The MMRC new 10 sum score yielded lower values by 5 to 6 points
than the original MMRC score (difference not tested statistically) so
that as anticipated it captured more weakness in a pattern considered
by experts to be typical of MMN. Participants had a mean INCAT dis-
ability scale score of 2.5 points on therapy, demonstrating persistent
disability despite treatment. Mean grip strength 2 weeks after the last
course of each product was higher than that just before the course
concerned, demonstrating ongoing benefit from IVIg treatment
(Supporting Information Table S1).
IVIg has been proven to improve weakness and disability in
patients with MMN and is the gold standard treatment of this dis-
abling disease. However, the effect of IVIg on motor symptoms and
signs may decline after several years.4 Consequently, other therapeu-
tic options are being investigated. Subcutaneous immunoglobulin has
been tested in small studies in MMN14–17; although maintenance was
not obtained in all subjects, this option could be more convenient for
some patients, as for chronic inflammatory demyelinating polyneuro-
pathy.18 The addition of eculizumab, which neutralises human com-
plement C5, to IVIg in one small-controlled trial showed a trend
towards improvement19 which needs to be confirmed in larger
studies.
This study was limited by the lack of high-quality outcome mea-
sures covering all the domains of disability, impairment, and quality of
life in MMN.20 The outcome measures used in MMN trials still lack
standardisation and sensitivity.21 At the time the protocol for this trial
was designed, there was no validated functional disability scale for
MMN. The Rasch-built overall disability scale for MMN (MMN-RODS)
does overcome the shortcomings of ordinal scales was proposed in
201522 but still needs to be validated in new series.
In summary, IqYmune® was not inferior to Kiovig® in efficacy for
the maintenance treatment of MMN. Safety results for both products
were consistent with the known safety profile of IVIg. This IqYmune®
is a valid option for the maintenance treatment of MMN.
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